| [1] |
Mok TS, Wu Y, Thongprasert S, et al. Gefitinib or Carboplatin- Paclitaxel in Pulmonary Adenocarcinoma[J]. N Engl J Med, 2009, 36 1(10): 947-57.
|
| [2] |
Wu SG, Yang CH, Yu CJ, et al. Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations[J]. Lung Cancer, 2011, 72(3): 333-9.
|
| [3] |
Zhang Q, Yang Z, Dai HT, et al. Role of EGFR mutation status in patients with advanced lung adenocarcinoma treated with pemetrexed[J]. Zhongguo Zhong Liu Lin Chuang, 2013, 40(22): 13 78-81. [张琼, 杨哲, 戴洪海, 等. 晚期肺腺癌EGFR突变状 态对培美曲塞疗效的影响[J]. 中国肿瘤临床, 2013, 40(22): 13 78-81.]
|
| [4] |
Mei JZ, Liu GJ, Feng RT, et al. Cisplatin induces upregulation of NKG2D ligands and enhances natural killer cell lysis of nasopharyngeal carcinoma cells[J]. Zhong Liu Fang Zhi Yan Jiu, 20 09, 36(12): 996-8. [梅家转, 刘桂举, 冯睿婷, 等. 顺铂对鼻咽 癌细胞NKG2D配体表达和NK细胞杀伤活性的增强作用[J]. 肿 瘤防治研究, 2009, 36(12): 996-8.]
|
| [5] |
Li PZ, Zhao BX, Liang QY, et al. MTT assay for detecting paclitaxel chemosensitivity on non small cell lung cancer[J]. Yao Xue Yan Jiu, 2014, 33(1): 1-4. [李鹏翀, 赵博新, 梁倩莹, 等. MTT法检测非小细胞肺癌对紫杉醇的敏感性[J]. 药学研究, 20 14, 33(1): 1-4.]
|
| [6] |
Bian J, Wang L, Xun C, et al. Sequence-dependent effects and mechanism of pemetrexed and gefitinib on human lung adenocarcinoma cells[J]. Zhong Liu Fang Zhi Yan Jiu, 2014, 41 (12): 1266-70. [边劲, 王琳, 寻琛, 等. 培美曲塞和吉非替尼不 同时序应用对人肺腺癌细胞的作用和机制[J]. 肿瘤防治研究, 20 14, 41(12): 1266-70.]
|
| [7] |
Jiang T, Song H, Zhao YY, et al. Effect of oxaliplatin combined with polyenephosphatidylcholine on proliferation of gastric cancer cells[J]. Zhongghua Zhong Liu Fang Zhi Za Zhi, 2014, 21(13): 10 10-3. [姜韬, 宋浩, 赵园园, 等. 奥沙利铂联合多烯磷脂酰 胆碱对胃癌细胞增殖影响研究[J]. 中华肿瘤防治杂志, 2014, 21 (13): 1010-3.]
|
| [8] |
Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method[J]. Cancer Res, 2010, 70(2): 44 0-6.
|
| [9] |
Yamashita F, Azuma K, Yoshida T, et al. Prognostic value of EGFR mutation and ERCC1 in patients with non-small cell lung cancer undergoing platinum-based chemotherapy[J]. PLoS One, 2013, 8( 8): e71356.
|
| [10] |
Wang S, Pan H, Liu D, et al. Excision repair cross complementation group 1 is a chemotherapy-tolerating gene in cisplatin-based treatment for non-small cell lung cancer[J]. Int J Oncol, 2015, 46 (2): 809-17.
|
| [11] |
Xian-Jun F, Xiu-Guang Q, Li Z, et al. ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy[J]. Pak J Med Sci, 20 14, 30(3): 488-92.
|
| [12] |
Li Z, Qing Y, Guan W, et al. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced nonsmall cell lung cancer (NSCLC) receiving first-line platinumpaclitaxel chemotherapy[J]. Cancer Chemother Pharmacol, 2014, 74 (4): 777-86.
|
| [13] |
Gandara DR, Grimminger P, Mack PC, et al. Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer[J]. J Thorac Oncol, 2010, 5(12): 1933-8.
|
| [14] |
Xu XB, Chu HL, Zhong C, et al. Association of EGFR mutation with ERCC1 mRNA expression in non-small cell lung cancer[J]. Zhongguo Zhong Liu Sheng Wu Zhi Liao Za Zhi, 2014, 21(6): 68 7-9. [徐小博, 楚慧丽, 仲晨, 等. 非小细胞肺癌组织中EGFR 基因突变与ERCC1mRNA表达的关系[J]. 中国肿瘤生物治疗杂 志, 2014, 21(6): 687-9.]
|
| [15] |
Li H, Zhang SP, Xie L, et al. Association of EGFR mutation with ERCC1 expression in non-small cell lung cancer[J]. Shan Dong Yi Yao, 2012, 52(6): 67-8. [李惠, 张树鹏, 谢玲, 等. 非小细胞肺 癌组织中EGFR基因突变与ERCC1基因表达的关系[J]. 山东医 药, 2012, 52(6): 67-8.]
|
| [16] |
Kaira K, Takahashi T, Murakami H, et al. The role of βIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy[J]. Int J Clin Oncol, 2013, 18(3): 371-9.
|
| [17] |
Wang B, Wang B, Zhang LB, et al. Correlation between expression of TUBB3/STMN1 and EGFR signaling pathway in non-small cell lung cancer[J]. Zhongguo Fei Ai Za Zhi, 2013, 16(10): 54 7-52. [王波, 王彬, 张连斌, 等. TUBB3/STMN1基因表达与 非小细胞肺癌EGFR通路的相关性[J]. 中国肺癌杂志, 2013, 16 (10): 547-52.]
|
| [18] |
Stordal B, Davey R. A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1[J]. Curr Cancer Drug Targets, 20 09, 9(3): 354-65.
|
| [19] |
Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutationpositive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol, 2011, 12(8): 735-42.
|
| [20] |
Okamoto I, Aoe K, Kato T, et al. Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced non-squamous non-small-cell lung cancer[J]. Invest New Drugs, 2013, 31(5): 1395-6.
|
| [21] |
Bai H, Wang Z, Chen K, et al. Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer[J]. J Clin Oncol, 2012, 30(25): 3077-83.
|
下载:
